Resolutions from the Extraordinary General Meeting in Swedish Orphan Biovitrum (Sobi)
At the Extraordinary General Meeting (EGM) convened earlier today in Stockholm,
the following was resolved in accordance with the proposals by the Board of
Directors.
Performance based, long-term share program for the CEO and transfer of own
shares
The EGM approved the Board of Directors' proposal regarding a performance based,
long-term share program for the new CEO Geoffrey McDonough. The share program is
based on an own investment in Sobi shares in the market and the allotment
requires, among other things, the fulfilment of certain performance based
targets related to the development of Sobi's share price.
The EGM also resolved to extend the Board of Directors' authorizations, granted
by the Annual General Meeting 2011, to issue and repurchase C-shares to also
cover the share program for the CEO. In addition, the EGM approved the Board of
Directors' proposal regarding transfer of own shares under the CEO share program
in order to secure the company's obligations under the program.
Revised guidelines for remuneration to senior management
The EGM further resolved to approve the Board of Directors' proposal on
guidelines for remuneration to management.
Full details on each proposal adopted by the EGM can be downloaded from
www.sobi.com.
For more information, contact:
Åsa Stenqvist, VP Communications and Investor Relations
Phone: +46 8 697 21 88
About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing
and developing specialty pharmaceuticals for patients with rare diseases and
significant medical needs. The portfolio comprises about 60 marketed products,
as well as projects in late clinical phase. Key therapeutic areas are
hematological diseases, autoimmune diseases, hereditary metabolic disorders and
therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and
approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. For more information please visitwww.sobi.com
The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on August 24, 2011 at 6.45 pm
CET.